These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24398824)

  • 21. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels.
    Montgomery SA; Altamura AC; Katila H; Datto C; Szamosi J; Eriksson H
    Int Clin Psychopharmacol; 2014 Mar; 29(2):93-105. PubMed ID: 24162081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone.
    Kasper S; Montagnani G; Trespi G; Di Fiorino M
    Int Clin Psychopharmacol; 2015 Jan; 30(1):14-22. PubMed ID: 25356632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate.
    Sheehan DV; Locklear J; Svedsäter H; Datto C
    Int Clin Psychopharmacol; 2012 Sep; 27(5):239-48. PubMed ID: 22859063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study.
    Weisler R; Joyce M; McGill L; Lazarus A; Szamosi J; Eriksson H;
    CNS Spectr; 2009 Jun; 14(6):299-313. PubMed ID: 19668121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER).
    Naber D; Peuskens J; Schwarzmann N; Goltz M; Krüger H; Lambert M; Haro JM
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1257-69. PubMed ID: 23953270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.
    Bandelow B; Chouinard G; Bobes J; Ahokas A; Eggens I; Liu S; Eriksson H
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):305-20. PubMed ID: 19691907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial.
    Potvin S; Morin M; Cloutier C; Gendron A; Bissonnette A; Marchand S
    J Clin Psychopharmacol; 2012 Oct; 32(5):684-7. PubMed ID: 22926604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder.
    Khan A; Joyce M; Atkinson S; Eggens I; Baldytcheva I; Eriksson H
    J Clin Psychopharmacol; 2011 Aug; 31(4):418-28. PubMed ID: 21694613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies.
    Stein DJ; Bandelow B; Merideth C; Olausson B; Szamosi J; Eriksson H
    Hum Psychopharmacol; 2011 Dec; 26(8):614-28. PubMed ID: 22143997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.
    Lindenmayer JP; Brown D; Liu S; Brecher M; Meulien D
    Psychopharmacol Bull; 2008; 41(3):11-35. PubMed ID: 18779774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial.
    Gao K; Wu R; Kemp DE; Chen J; Karberg E; Conroy C; Chan P; Ren M; Serrano MB; Ganocy SJ; Calabrese JR
    J Clin Psychiatry; 2014 Oct; 75(10):1062-8. PubMed ID: 25007003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies.
    Trivedi MH; Bandelow B; Demyttenaere K; Papakostas GI; Szamosi J; Earley W; Eriksson H
    Int J Neuropsychopharmacol; 2013 Sep; 16(8):1733-44. PubMed ID: 23673347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression.
    Thase ME; Demyttenaere K; Earley WR; Gustafsson U; Udd M; Eriksson H
    Depress Anxiety; 2012 Jul; 29(7):574-86. PubMed ID: 22753280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder.
    Montgomery SA; Locklear JC; Svedsäter H; Eriksson H
    Int Clin Psychopharmacol; 2014 Sep; 29(5):252-62. PubMed ID: 24394383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, Placebo-Controlled Effectiveness Study of Quetiapine XR in Comorbid Depressive and Anxiety Disorders.
    Ravindran N; McKay M; Paric A; Johnson S; Chandrasena R; Abraham G; Ravindran AV
    J Clin Psychiatry; 2022 Mar; 83(3):. PubMed ID: 35324094
    [No Abstract]   [Full Text] [Related]  

  • 38. The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): An open label naturalistic study.
    Gabriel A
    Clin Ter; 2011; 162(2):113-8. PubMed ID: 21533316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 6-week, multicenter, double-blind, double-dummy, chlorpromazine-controlled non-inferiorityrandomized phase iiitrial to evaluate the efficacy and safety of quetiapine fumarate (SEROQUEL) extended-release (XR) in the treatment of patients with schizophrenia and acute episodes.
    Li H; Shen Y; Wang G; Shi J; Ma C; Xie S; Zhang H; Wang X; Li K; Xu X; Gu N
    Psychiatry Res; 2018 Jan; 259():117-124. PubMed ID: 29040947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder.
    Vieta E; Bauer M; Montgomery S; McIntyre RS; Szamosi J; Earley WR; Eriksson H
    J Affect Disord; 2013 Sep; 150(2):639-43. PubMed ID: 23497790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.